VANCOUVER, September 16, 2018  – Altum Pharmaceuticals Inc. (“Altum” or “Altum Pharmaceuticals”) a biopharmaceutical company focused on the development of innovative therapeutic products is pleased to announce the appointment of Ms. Nancy Miller-Rich to the position of Executive Chair and Director, effective immediately. Ms. Miller-Rich has 35 years experience in the pharmaceutical industry in senior leadership roles in business development and global commercial strategy. Most recently at Merck, she served as Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support (2013 – 2017) where she had direct P&L involvement in the $38B pharmaceutical division and closed approximately 300 deals producing $10B of value creation across key therapeutic areas including oncology, diabetes and vaccines.

Prior to Merck Ms. Miller-Rich spent more than 20 years at Schering-Plough (original supplier of Interferon alpha2b used in Altum’s AP-001) where in her last position she served as Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development (2007 – 2013). At Schering she led global initiatives in licensing, JV’s, acquisitions of new products and technologies as well as financial analysis/valuation, negotiation and alliance management.

Prior to joining Schering-Plough, Ms. Miller-Rich was at Sandoz Pharmaceuticals and Sterling Drug, Inc. Ms. Miller-Rich is currently a director of Intercept Pharmaceuticals (Nasdaq: ICPT) and UDG Healthcare plc (LSE: UDG), as well as a member of the boards of a number of not-for-profit entities.

“I am pleased to welcome Nancy to the Altum team. She has tremendous wealth of experience and energy that will greatly help our management team in advancing our plans in the coming months. Her extensive network of pharmaceutical executives and leaders will create significant new opportunities in finance and business development for Altum.” said Ahmad Doroudian, Chief Executive Officer.


About Altum Pharmaceuticals Inc.

Altum Pharmaceuticals Inc. is a private biopharmaceutical company engaged in clinical and commercial development of novel natural and pharmaceutical compounds, to treat cancer and autoimmune disorders. Altum focuses on development and acquisition of novel products specializing on the commercialization of existing products for cancer and diseases mediated by acute and chronic inflammatory reactions. For more information please visit the website at


Altum Pharmaceuticals Inc.

Tel: (604) 221-0595




This news release contains certain forward-looking statements and information (collectively, “forward- looking statements”) within the meaning of applicable Canadian securities laws, without limitation, those relating to words including, without limitation, “unique”, “believes” “will”, “may”, “anticipated”, “intended”, “build”. “effective”, “continuing progress” and other similar expressions, are intended to provide information about management’s current plans and expectations.

Although Altum believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Altum’s management on the date of this shareholder update, and Altum does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.